Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Heart Failure With Preserved Ejection Fraction (HFpEF) Clinical Trial

Official title:
A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Active Controlled Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Valsartan on Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Status Completed

Clinical Trial Summary

The effect of sacubitril/valsartan vs. valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF decompensation) who have been stabilized and initiated at the time of or within 30 days post-decompensation.

Clinical Trial Description

The purpose of this study is to assess the effect of sacubitril/valsartan vs. valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF decompensation) who have been stabilized and initiated at the time of or within 30 days post-decompensation ;

Study Design

Related Conditions & MeSH terms

Heart Failure
Heart Failure With Preserved Ejection Fraction (HFpEF)

Clinical Trial Details

NCT number	NCT03988634
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 3
Start date	June 27, 2019
Completion date	December 14, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05371496` - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction	Phase 2
Recruiting	`NCT05441839` - UK Heart Failure With Preserved Ejection Fraction
Completed	`NCT01989299` - Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction
Terminated	`NCT03909295` - An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.	Phase 3
Completed	`NCT04327024` - Study of Verinurad in Heart Failure With Preserved Ejection Fraction	Phase 2
Active, not recruiting	`NCT05136820` - Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study	N/A
Recruiting	`NCT03876223` - Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
Completed	`NCT04232345` - A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers	Phase 1
Recruiting	`NCT05792059` - DevElopMent of Clinical PATHwaYs to the Diagnosis of Heart Failure With Preserved Ejection Fraction
Completed	`NCT03843060` - A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers	Phase 1
Completed	`NCT01714752` - Evaluation of Left Ventricular Filling Pressures During Exercise	N/A
Completed	`NCT06036186` - Study for the Treatment of Heart Failure With Preserved Ejection Fraction Associated With High Blood Pressure Using Right Atrial Pacing Controlled by the PressurePaceTM System	N/A
Recruiting	`NCT05383287` - Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)
Completed	`NCT03877224` - DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction	Phase 3
Active, not recruiting	`NCT04847557` - A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial	Phase 3
Recruiting	`NCT04822649` - Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition	N/A